YAMADA Y, TANIGAWARA Y, AOKI N, TOTSUKA K; Interscience Conference on Antimicrobial Agents and Chemotherapy (42nd : 2002 : San Diego, Calif.).
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2002 Sep 27-30; 42: abstract no. A-1397.
Asahikasei Corporation, Shizuoka, Japan.
BACKGROUND: CZX-AP possesses dual promoieties, resulting in well-balanced lipophilic and hydrophilic properties and good bioavailability. CZX-AP is currently under development in clinical phase 3 trials that include pediatric patients, and its pharmacokinetic profile is being analyzed. METHODS: A PPK was done of 2,547 blood samples obtained from 290 patients, ages from 7 months to 90 years. Pediatric patients were administered 3mg/kg CZX-AP granules and adult patients 100 mg tablets, twice daily, either before or after meals. Blood concentrations were analyzed in a one-compartment model including absorption lag time. Fifty-two adult patients had RD (Ccr
Publication Types:
Keywords:
- Adult
- Area Under Curve
- Ceftizoxime
- Child
- Clinical Trials as Topic
- Humans
- Population
- Population Groups
- Prodrugs
- ceftizoxime alapivoxil
- pharmacokinetics
Other ID:
UI: 102266603
From Meeting Abstracts